Agility Life Sciences

Executive Summary

Agility Life Sciences is a UK-based contract development and manufacturing organization (CDMO) specializing in advanced formulation development for poorly soluble, permeable, or unstable small molecules and peptides. Founded in 2010 and headquartered in Cambridge, the company employs 201-500 staff and serves clients across oral, ocular, intranasal, and topical routes. Its proprietary 'Futureproof Formulations Fast™' approach aims to accelerate drug candidates from preclinical through clinical and commercial stages. Despite being classified as preclinical, the company has established itself as a reliable partner for complex formulation challenges, positioning it for growth as the CDMO market expands. The company is privately held with no public fundraising disclosed, suggesting a focus on organic growth or potential strategic backing.

Upcoming Catalysts (preview)

• Q3 2026New Strategic Partnership with a Top-20 Pharma Company65% success
• Q4 2026Expansion of GMP Manufacturing Capacity at Cambridge Facility80% success
• Q2 2026Launch of Novel Lipid Nanoparticle (LNP) Platform for Peptide Delivery50% success